Quantcast

Shield Therapeutics: Ferric maltol may be effective in patients with active inflammatory markers

Shield Therapeutics’s study suggests that ferric maltol may be effective in patients with active inflammatory markers, and that the ongoing comparative trial of ferric maltol against iv iron will be useful to challenge the prevalent doctrine prohibiting treatment of patients with active systemic inflammation with oral iron.

Read more